Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1992 Dec 12;305(6867):1457–1460. doi: 10.1136/bmj.305.6867.1457

Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective.

C Gustafsson 1, K Asplund 1, M Britton 1, B Norrving 1, B Olsson 1, L A Marké 1
PMCID: PMC1884109  PMID: 1493390

Abstract

OBJECTIVE--To assess the potential effects of primary prevention with anticoagulants or aspirin in atrial fibrillation on Swedish population. DESIGN--Analysis of cost effectiveness based on the following assumptions: about 83,000 people have atrial fibrillation in Sweden, of whom 22,000 would be potential candidates for treatment with anticoagulants and 55,000 for aspirin treatment; the annual 5% stroke rate is reduced by 64% (with anticoagulants) and 25% (with aspirin); incidence of intracranial haemorrhage of 0.3%, 1.3%, or 2.0% per year; direct and indirect costs of a stroke of Kr180,000 and Kr90,000; estimated annual cost of treatment is Kr5030 for anticoagulants and Kr100 for aspirin. SETTING--Total Swedish population. MAIN OUTCOME MEASURES--Direct and indirect costs of stroke saved, number of strokes prevented, and cost of preventive treatment. RESULTS--Depending on the rate of haemorrhagic complications 34 to 83 patients would need to be treated annually with anticoagulants to prevent one stroke; 83 patients would need to be treated with aspirin. Giving anticoagulant treatment only would reduce costs by Kr60 million if the incidence of intracranial haemorrhage were 0.3% but would imply a net expense if the complication rate exceeded 1.3%. The total savings from giving anticoagulant (22,000 patients) and aspirin (55,000 patients) treatment would be Kr175 million per year corresponding to 2 million pounds per million inhabitants each year. CONCLUSIONS--Treatment with anticoagulants and, if contraindications exist, with aspirin is cost effective provided that the risk of serious haemorrhage complications due to anticoagulants is kept low.

Full text

PDF
1457

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albers G. W., Atwood J. E., Hirsh J., Sherman D. G., Hughes R. A., Connolly S. J. Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med. 1991 Nov 1;115(9):727–736. doi: 10.7326/0003-4819-115-9-727. [DOI] [PubMed] [Google Scholar]
  2. Cairns J. A., Connolly S. J. Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation. 1991 Aug;84(2):469–481. doi: 10.1161/01.cir.84.2.469. [DOI] [PubMed] [Google Scholar]
  3. Connolly S. J., Laupacis A., Gent M., Roberts R. S., Cairns J. A., Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991 Aug;18(2):349–355. doi: 10.1016/0735-1097(91)90585-w. [DOI] [PubMed] [Google Scholar]
  4. Kutner M., Nixon G., Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med. 1991 Oct;151(10):1950–1953. [PubMed] [Google Scholar]
  5. Lancaster T. R., Singer D. E., Sheehan M. A., Oertel L. B., Maraventano S. W., Hughes R. A., Kistler J. P. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med. 1991 Oct;151(10):1944–1949. [PubMed] [Google Scholar]
  6. Landahl S., Svanborg A., Astrand K. Heart volume and the prevalence of certain common cardiovascular disorders at 70 and 75 years of age. Eur Heart J. 1984 Apr;5(4):326–331. doi: 10.1093/oxfordjournals.eurheartj.a061659. [DOI] [PubMed] [Google Scholar]
  7. Landefeld C. S., Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989 Aug;87(2):144–152. doi: 10.1016/s0002-9343(89)80689-8. [DOI] [PubMed] [Google Scholar]
  8. Lundström T., Rydén L. Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J Intern Med. 1989 Feb;225(2):137–142. doi: 10.1111/j.1365-2796.1989.tb00053.x. [DOI] [PubMed] [Google Scholar]
  9. Petersen P., Boysen G., Godtfredsen J., Andersen E. D., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989 Jan 28;1(8631):175–179. doi: 10.1016/s0140-6736(89)91200-2. [DOI] [PubMed] [Google Scholar]
  10. Wintzen A. R., de Jonge H., Loeliger E. A., Bots G. T. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol. 1984 Nov;16(5):553–558. doi: 10.1002/ana.410160505. [DOI] [PubMed] [Google Scholar]
  11. Wolf P. A., Abbott R. D., Kannel W. B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22(8):983–988. doi: 10.1161/01.str.22.8.983. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES